The science behind Sculptra®
Sculptra® is the original collagen stimulator that gradually replaces the structural support lost to aging.1
What happens with skin collagen as we age?
Collagen is a key structural component of smooth, healthy-looking skin. As you age, your body’s collagen production decreases. In fact, facial aging begins in your 20s, when you start losing about 1% of the collagen in your skin per year.2 This is when you may start to notice the formation of wrinkles.
Skin firmness decreases as a result of both internal factors (genetics and natural aging) and external factors (sun exposure, smoking, stress, etc.).3 Visible effects of the loss of collagen include loose and saggy skin, shallow to deep wrinkles and folds and loss of skin volume.
Reinvigorate your skin’s own collagen production
Sculptra® contains microparticles of poly-L-Lactic acid, PLLA, which is a synthetic, biodegradable, biocompatible polymer. PLLA has been used in dissolvable stitches for wound management and medical implants for decades.
Patient studies have shown that injections with Sculptra® result in an increase in skin thickness and a reduction of facial wrinkles4 – and the effects are long-lasting. As many as 80% of patients who had treatment with Sculptra still rated their results as “good to excellent” after 25 months.5
Committed to innovation
Galderma empowers everyone to realize their own aesthetic goals by providing the most diverse portfolio of injectable treatments on the market. With constant innovation and pioneering new technologies, we push the industry forward in our ambition to develop safe aesthetic treatments that live up to or exceed patients’ expectations. Learn more about our solutions and our commitment to innovation here.
80% of patients rated Sculptra® results as “good to excellent” after 25 months6
100% of patients would recommend Sculptra® to a friend7
Proven aesthetic results since 19998
1 Stein P et al. J Dermatol Sci 2015;78(1):26–33.9.; Goldberg D et al. Dermatol Surg 2013;39(6):915–22.; Vleggaar D et al. J Drugs Dermatol 2014;13(4 suppl):s29–31.; Moyle GJ et al. HIV Med 2004;5(2):82–7.; Bohnert K et al. Plast Reconstr Surg 2019;127(4): 1684–92.
2 Shuster S, Black MM, McVitie E. Br J Dermatol. 1975;93:639-643.
3 Vleggaar D, Fitzgerald R. J Drugs Dermatol. 2008;7:209-220.
4 Nelson L and Stewart KJ. J Plast Reconstr Aesthet Surg 2012;65(4):439–47.; Moyle GJ et al. HIV Med 2004;5(2):82–7.; Mest DR and Humble G. Dermatol Surg 2006;32(11): 1336–45.; Valantin MA et al. AIDS 2003;17(17):2471–7.; Narins RS et al. J Am Acad Dermatol 2010;62(3):448–62.; Brandt FS et al. Aesthet Surg J 2011;31(5):521–8.
5 Brown SA et al. Plast Reconstr Surg 2011;127(4):1684–92.
6 Brown SA et al. Plast Reconstr Surg 2011;127(4):1684–92.
7 Mest DR and Humble G. Dermatol Surg 2006;32(11):1336–45.
8 Sculptra was developed and CE approved for aesthetic use in the European market in 1999.